002872.SHE Tiansheng Pharmaceutical Group Co Ltd
- Market cap
- CNY 1.83B
- P/E
- -
- P/B
- 0.89x
- ROE
- -3.1%
- Dividend yield
- 0.82%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002872.SHE undervalued?
Graham numberThe Graham number of Tiansheng Pharmaceutical Group Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Tiansheng Pharmaceutical Group Co Ltd fundamental analysis
No fundamental analysis for Tiansheng Pharmaceutical Group Co Ltd yet.
Tiansheng Pharmaceutical Group Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Tiansheng Pharmaceutical Group Co Ltd
Tiansheng Pharmaceutical Group Co., Ltd. engages in pharmaceutical manufacturing and circulation activities. The company offers pediatric cough granules, erythromycin enteric-coated capsules, yinshen tongluo capsules, yanshen jianwei capsules, and sodium chloride injection products. It provides products in various categories, including respiratory, cardiovascular and cerebrovascular, urinary system, pediatrics, digestive, gynecological, orthopedic, cardiology, diabetes, anes…
Full company profileTiansheng Pharmaceutical Group Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Tiansheng Pharmaceutical Group Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.09B | 2.26B | 2.17B | 1.68B | 1.20B | 737M | 607M | 579M | 570M | 514M | 456M |
| Gross Profit | 596M | 667M | 615M | 414M | 329M | 295M | 328M | 257M | 261M | 253M | 211M |
| Operating Income | 238M | 308M | 60.7M | -222M | -500M | -61.0M | -84.7M | -93.6M | -94.0M | -38.2M | -72.6M |
| EBITDA | 388M | 429M | 188M | -84.4M | -379M | 58.7M | 37.2M | 24.5M | 22.7M | 71.6M | -47.4M |
| Net Income | 224M | 247M | 8.86M | -224M | -491M | -67.8M | -90.6M | -93.1M | -87.4M | -55.4M | -58.4M |
| EPS | 0.94 | 0.84 | 0.04 | -0.70 | -1.54 | -0.21 | -0.28 | -0.29 | -0.27 | -0.17 | -0.18 |
| Balance Sheet | |||||||||||
| Total Assets | 3.39B | 4.95B | 4.67B | 4.39B | 3.65B | 3.12B | 2.97B | 2.81B | 2.74B | 2.64B | 2.56B |
| Total Liabilities | 1.53B | 1.76B | 1.49B | 1.44B | 1.26B | 841M | 782M | 715M | 722M | 685M | 648M |
| Shareholders' Equity | 1.81B | 3.13B | 3.11B | 2.90B | 2.34B | 2.27B | 2.18B | 2.09B | 2.01B | 1.95B | 1.91B |
| Cash & Short-term Investments | 419M | 606M | 327M | 318M | 292M | 421M | 278M | 193M | 270M | 280M | 278M |
| Total Debt | 666M | 843M | 689M | 625M | 494M | 351M | 268M | 176M | 277M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 507M | -55.7M | 154M | 144M | 190M | 19.0M | 89.2M | -24.6M | 50.1M | 43.0M | - |
| Capital Expenditure | 426M | 862M | 234M | 93.2M | 92.7M | 114M | 73.4M | 76.7M | 50.3M | 26.9M | 37.3M |
| Free Cash Flow | 80.7M | -918M | -80.3M | 51.0M | 97.1M | -95.4M | 15.8M | -101M | -126K | 16.1M | 8.85M |
| Ratios | |||||||||||
| ROE | 12.4% | 7.9% | 0.3% | -7.7% | -21.0% | -3.0% | -4.1% | -4.5% | -4.4% | -2.8% | -3.1% |
| ROA | 6.6% | 5.0% | 0.2% | -5.1% | -13.5% | -2.2% | -3.0% | -3.3% | -3.2% | -2.1% | -2.3% |
| Net Profit Margin | 10.8% | 10.9% | 0.4% | -13.3% | -40.8% | -9.2% | -14.9% | -16.1% | -15.3% | -10.8% | -12.8% |
| Debt to Equity | 0.37x | 0.27x | 0.22x | 0.22x | 0.21x | 0.15x | 0.12x | 0.08x | 0.14x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Tiansheng Pharmaceutical Group Co Ltd dividends
- Dividend yield
- 0.82%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Aug 22, 2018
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 15.0M | 0.05 | - |
| 2024 | CNY 15.3M | 0.05 | - |
| 2023 | CNY 15.5M | 0.05 | - |
| 2022 | CNY 15.9M | 0.05 | - |
| 2021 | CNY 22.9M | 0.07 | - |
| 2020 | CNY 37.2M | 0.12 | - |
| 2019 | CNY 34.7M | 0.11 | - |
| 2018 | CNY 93.0M | 0.38 | 1,049.7% |
| 2017 | CNY 34.3M | 0.12 | 13.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.5:1 on Aug 22, 2018.
Who owns Tiansheng Pharmaceutical Group Co Ltd
- Insiders 47.20%
- Institutions 0.00%
- Public & others 52.80%
- Shares outstanding 318M
- Free float 210M
Tiansheng Pharmaceutical Group Co Ltd company profile
- Company name
- Tiansheng Pharmaceutical Group Co Ltd
- Ticker
- 002872.SHE
- ISIN
- CNE100002QC3
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,273
- Fiscal year end
- December
- Address
- Chaoyang Industrial Park, Chongqing, China, 408300
- Phone
- 86 23 6291 0742
- Website
- tszy.com.cn
About Tiansheng Pharmaceutical Group Co Ltd
Tiansheng Pharmaceutical Group Co., Ltd. engages in pharmaceutical manufacturing and circulation activities. The company offers pediatric cough granules, erythromycin enteric-coated capsules, yinshen tongluo capsules, yanshen jianwei capsules, and sodium chloride injection products. It provides products in various categories, including respiratory, cardiovascular and cerebrovascular, urinary system, pediatrics, digestive, gynecological, orthopedic, cardiology, diabetes, anesthetic, oncology, hepatobiliary, hematological, surgical, and others. In addition, it provides traditional Chinese medicines and glucose injection. Tiansheng Pharmaceutical Group Co., Ltd. was founded in 2001 and is headquartered in Chongqing, China.
Tiansheng Pharmaceutical Group Co Ltd management
5- Mr. Shuang LiuChairman of the Board & GM · born 1993
- Mr. Kai Sheng WangCFO & Accounting Supervisor · born 1974
- Mr. Zonghua TanDeputy GM & Director · born 1972
- Ms. Qin WangBoard Secretary · born 1985
- Mr. Lun Sheng MouDeputy General Manager · born 1976